Pregledni rad
https://doi.org/10.20471/acc.2022.61.s3.5
How to Optimally Sequence Available Therapy Lines in Advanced Prostate Cancer
Katarina Antunac
orcid.org/0000-0002-8356-9897
; Division of Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Sažetak
Optimal sequencing of available therapy lines in patients with advanced prostate
cancer often poses quite a challenge. The guidelines are sometimes equivocal and clinical trial data are
not always applicable to a particular patient. There is a difference in availability of therapy options
throughout the world. In decision making, a patient as a whole should be taken into consideration,
not just the stage and biology of the disease, but also patient’s age, performance status, comorbidities,
previous therapy lines, drug’s safety profile and patient’s preferences. This review article will show
certain therapeutic options in the treatment of advanced hormone-sensitive prostate cancer and castration
resistant prostate cancer: non- metastatic and metastatic. An attempt will be made to clarify
the optimal sequencing.
Ključne riječi
Advanced Prostate Cancer; Hormone Sensitive Prostate Cancer; Castration Resistant Prostate Cancer; Androgen Deprivation Therapy
Hrčak ID:
286365
URI
Datum izdavanja:
1.10.2022.
Posjeta: 764 *